Vinci Pharmaceuticals develops EPIPLANTβ’, a needle-free drug delivery platform for treating retinal diseases. The company focuses on innovative solutions to improve patient outcomes in the field of ophthalmology.
Founded
2019
Total Funding
$1M+
Total Rounds
1
First Raise
Oct 8, 2026
Latest Raise
Oct 8, 2026
New funding rounds in your inbox every week Β· No noise, all Signal.
Founders and leadership hierarchy for this company.
| Date | Deal Type | Amount | Lead Investor |
|---|---|---|---|
| 10/8/2026 | |||
Upgrade to Premium to view Capital Momentum Score and performance metrics
New funding rounds in your inbox every week Β· Free